This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| Follistatin 344 | KPV | |
|---|---|---|
| Highest evidence tier on the page | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. | E4 Preclinical only Animal or in vitro work. Not demonstrated in humans. |
| Regulatory status | Not approved in any form; only human data is from small, completed Phase 1/1-2 AAV gene-therapy trials for muscular dystrophy/myositis, not injectable protein use | Not approved for human use |
| Research area | Growth hormone axis, Tissue repair and recovery | Sexual health and melanocortin, Tissue repair and recovery |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | Not reliably established | C16H30N4O4 |
| Molar mass | Not reliably established | 342.44 g/mol |
| CAS number | Not reliably established | 67727-97-3 |
| Registered trials on this site | 2 in the tracker | None linked yet |
| Furthest registered phase | Phase 1 / Phase 2 | Not stated |
| Trials currently active | 0 | Not stated |
| Trial sponsors | Jerry R. Mendell, Nationwide Children's Hospital | Not stated |
| What is not known | The largest open question for this entry is a category mismatch: essentially all human research on "follistatin-344" used AAV-vectored gene therapy causing a patient's own muscle to manufacture the protein locally over time, not a manufactured protein injected directly and repeatedly the way vendor "Follistatin... | Whether KPV does anything in a human being. No trial has asked. Beyond that: no human pharmacokinetics or bioavailability by any route, no half-life, no toxicology package, and no chronic-use data in any species. No published binding affinity for any melanocortin receptor. No drug-interaction data,... |
Full pages: Follistatin 344 and KPV. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
